1. Home
  2. SERV vs KALV Comparison

SERV vs KALV Comparison

Compare SERV & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Serve Robotics Inc.

SERV

Serve Robotics Inc.

HOLD

Current Price

$9.40

Market Cap

913.2M

ML Signal

HOLD

Logo KalVista Pharmaceuticals Inc.

KALV

KalVista Pharmaceuticals Inc.

HOLD

Current Price

$16.20

Market Cap

757.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SERV
KALV
Founded
2017
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
913.2M
757.7M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
SERV
KALV
Price
$9.40
$16.20
Analyst Decision
Buy
Strong Buy
Analyst Count
6
5
Target Price
$18.80
$30.00
AVG Volume (30 Days)
3.0M
570.8K
Earning Date
01-01-0001
04-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$50,000,000.00
Revenue This Year
$41.13
N/A
Revenue Next Year
$908.17
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
495.66
52 Week Low
$4.66
$9.83
52 Week High
$18.64
$19.00

Technical Indicators

Market Signals
Indicator
SERV
KALV
Relative Strength Index (RSI) 41.56 55.78
Support Level $9.32 $14.45
Resistance Level $11.00 $16.33
Average True Range (ATR) 0.61 0.71
MACD 0.07 0.07
Stochastic Oscillator 25.30 77.03

Price Performance

Historical Comparison
SERV
KALV

About SERV Serve Robotics Inc.

Serve Robotics Inc is developing next-generation robots for last-mile delivery services. It design, develop and operate low-emissions robots on AI-powered robotics mobility platform, that serve people in public spaces, starting with food delivery. Its first product is a zero-emission robot that serves people in public areas, Starting with food delivery. It has developed an AI-robotics mobility platform, with last-mile delivery in cities as its first application.

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

Share on Social Networks: